Moderna
- Country
- πΊπΈUnited States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company...
Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19
- Conditions
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 13680
- Registration Number
- NCT05894590
- Locations
- π―π΅
CMIC Co., Ltd, Tokyo, Japan
Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine
- Conditions
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 8844
- Registration Number
- NCT05894525
- Locations
- π―π΅
CMIC Co. Ltd.,, Tokyo, Japan
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT05868382
- Locations
- πΊπΈ
DM Clinical Research, Sugar Land, Texas, United States
πΊπΈMeridian Clinical Research, Lincoln, Nebraska, United States
πΊπΈJohnson County Clin-Trials, Lenexa, Kansas, United States
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 354
- Registration Number
- NCT05831111
- Locations
- πΊπΈ
Velocity Clinical Research, Binghamton, New York, United States
πΊπΈPinnacle Research Group, LLC, Anniston, Alabama, United States
πΊπΈDM Clinical Research, Tomball, Texas, United States
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
- Conditions
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 8422
- Registration Number
- NCT05827978
- Locations
- πΊπΈ
Velocity Clinical Research, Rockville, Rockville, Maryland, United States
πΊπΈIndago Research and Health Center, Hialeah, Florida, United States
πΊπΈCullman Research Center, Cullman, Alabama, United States
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
- Conditions
- Interventions
- Biological: mRNA-1083Biological: Investigational COVID-19 Vaccine 1Biological: mRNA-1083.1Biological: mRNA-1083.2Biological: COVID-19 Vaccine 1Biological: Investigational Influenza Vaccine 1Biological: Influenza Vaccine 2Biological: mRNA-1083.3Biological: Investigational Influenza Vaccine 2Biological: Influenza Vaccine 1Biological: COVID-19 Vaccine 2Biological: Investigational COVID-19 Vaccine 2
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1763
- Registration Number
- NCT05827926
- Locations
- πΊπΈ
Centricity Research, Columbus, Ohio, United States
πΊπΈTexas Center for Drug Development, Houston, Texas, United States
πΊπΈTekton Research, San Antonio, Texas, United States
A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 700
- Registration Number
- NCT05827068
- Locations
- πΊπΈ
Healor Primary Care, Las Vegas, Nevada, United States
πΊπΈCenExel RCA, Hollywood, Florida, United States
πΊπΈSuncoast Research Associates, LLC, Miami, Florida, United States
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants β₯12 Years of Age to Prevent COVID-19
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 14246
- Registration Number
- NCT05815498
- Locations
- πΊπΈ
Coastal Carolina Research Center, North Charleston, South Carolina, United States
πΊπΈFloridian Clinical Research, Miami Lakes, Florida, United States
πΊπΈVelocity Clinical Research-Anderson, Anderson, South Carolina, United States
A Retrospective Study to Characterize Participants With Propionic Acidemia and Methylmalonic Acidemia
- Conditions
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05769621
- Locations
- πΊπΈ
University of Stanford Medical Center, Stanford, California, United States
πΊπΈJohns Hopkins University, Lutherville, Maryland, United States
πΊπΈUniversity of Michigan Hospital, Ann Arbor, Michigan, United States
An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1713
- Registration Number
- NCT05765578
- Locations
- πΊπΈ
Science37, Culver City, California, United States